SCHEMBL6763553

SCHEMBL6763553

O[C@H]1[C]Cc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
ACP3 P15309 1/20 0.35
RET P07949 1/20 0.33
HTR2C P28335 1/20 0.33
HRH1 P35367 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
GRIN3A Q8TCU5 1/20 0.32
ANPEP P15144 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6613669 1.00 HTR2A (0.37) HTR2AMAOAMAOBACP3RET
SCHEMBL6634371 0.78 ACP3 (0.41) HTR2AACP3RETGRIN1GRIN2B
SCHEMBL7472084 0.73 HTR2A (0.46) HTR2ARETHTR2CHRH1ANPEP
SCHEMBL7471745 0.71 CHRNB2 (0.34)
SCHEMBL16540791 0.70 HTR2A (0.34) HTR2AMAOAMAOBACP3RET
SCHEMBL874497 0.70 HTR2A (0.34) HTR2AMAOAMAOBACP3RET
SCHEMBL8776161 0.68 HTR2A (0.33) HTR2ARETHTR2CHRH1
SCHEMBL7469960 0.68 HTR2A (0.33) HTR2AHRH1
SCHEMBL7111517 0.68 HTR2A (0.42) HTR2AMAOAMAOBACP3RET
SCHEMBL6604314 0.68 ANPEP (0.37) ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US disclosed
WO-2003076408-A2 INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ABBOTT LABORATORIES (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase GUCY1B1, GUCY1A1, GUCY1A2 HTR2A 2311/4885MAOA 795/4885MAOB 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.